704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II

Safety and efficacy of transposon BAFF ligand directed chimeric antigen receptor T cells LMY 920 with pre apheresis obinutuzumab for patients with Relapsed Refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Phase I study of FH FOLR1 CAR T for pediatric patients with FOLR1 CBFA2T3 GLIS2 relapsed or refractory Acute Myeloid Leukemia

CAR T cells co targeting BCMA and CD19 in RRMM Results from the UKMRA Phase 1 MCARTY trial in relapsed refractory multiple myeloma

Neuroinflammation detected by TSPO PET precedes dopaminergic neuronal loss in mnt following BCMA directed CAR T therapy Longitudinal multimodal neuroimaging and biomarker insights

Prolonged thrombocytopenia following diverse CAR T cell therapies High incidence inflammatory risk factors and a comparative efficacy analysis of TPO receptor agonist strategies in a real world cohort

Lymphodepletion free jl lightning CAR T targeting CD19 CD22 BCMA achieved 100 CR in 3 Relapsed Refractory B NHL patients A lymphodepletion regimen comparison study

An IL 10 incorporated predictive model for late immune effector cell associated hematotoxicity following CAR T therapy in B cell malignancies

LV20 19 CAR T cells for methotrexate relapsed refractory primary or secondary CNS lymphoma with parenchymal involvement

WU CART 007 a CD7 directed allogeneic CAR T cell therapy for R R T cell acute lymphoblastic leukemia lymphoma Phase 1 2 correlative data and long term follow up update

Anti CD7 CAR T cells in patients with relapsed or refractory CD7 Acute Myeloid Leukemia First in human phase I study

Non relapse mortality in patients who received CAR T cell therapy at an urban hospital

CD22 directed CAR T cells induce complete remissions in high risk follicular and Mantle Cell Lymphoma with limited neurotoxicity

The impact of clonal hematopoiesis on CAR T cell therapy outcomes A single center analysis

Assessment of prolonged thrombocytopenia after CD19 CAR T therapy Evidence for reduced production

Anti CD7 CAR T cell therapy for ultra high risk relapsed refractory T ALL lbl Insights into lineage switch and consolidation strategies

Allogenic donor derived cytokine induced killer CIK cells as a safe post transplant treatment for disease recurrence in the setting of HLA mismatched donors

A multicentre Phase I clinical trial demonstrates manufacturing feasibility safety and activity of novel humanized BCMA directed CAR T cell therapy

A novel loop structured CD19 CD22 dual targeting CAR T therapy for patients with refractory relapsed B cell non Hodgkin lymphoma

Atypical neurotoxicity in CAR T cell therapy A retrospective analysis of unusual icans presentations and their clinical implications

Five year follow up of donor derived CD7 CAR T cell therapy for r r T cell acute lymphoblastic leukemia

Immune reconstitution and infectious complications following CAR T cell therapy

Independent assessment of ALC thresholds currently in use to predict motor neurocognitive toxicities MNTs after treatment with ciltacabtagene autoleucel

SL0439 A structure tuned bispecific nanobody CAR T cells targeting BCMA GPRC5D for relapsed refractory multiple myeloma with extramedullary disease

Parkinsonism after treatment with anti CD19 CAR T Case report institutional data review and pharmacovigilance analysis of the FDA adverse event reporting system database

First in human study of CTX130 a CD70 directed allogeneic CAR T therapy in adult T cell leukemia lymphoma Clinical and genomics findings from a long term follow up of subgroup analysis from the cobalt LYM Phase 1 trial

CD19 CD22 CAR T cells in adult patients with relapsed refractory B cell malignancies

In depth quantitative characterization of important regulators and predictive biomarkers for CAR T cell therapy induced toxicities in a clinical cohort